CT-eligible patients include T2DM patients on one or two insulin injections or GLP-analogues and those experiencing insufficient regulation with maximum oral antidiabetic treatment excluding pregnant women and T1DM patients [26]. This evidence concerns the gene INS and type 2 diabetes mellitus.